Mayur Ian Somaiya
Chief Financial Officer · NewAmsterdam Pharma Co N.V.
- 2026
- Jan 22, 2026
- 2
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Mayur Ian Somaiya files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Michael H. Davidson - $25.55M in NAMS purchases and sales in the last 12 months
- Louise Frederika Kooij - $16.75M in NAMS purchases and sales in the last 12 months
- Johannes Jacob Pieter Kastelein - $15.52M in NAMS purchases and sales in the last 12 months
- Louis G. Lange - $2.19M in NAMS purchases and sales in the last 12 months
- John W. Smither - $41K in NAMS purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Mayur Ian Somaiya?
Mayur Ian Somaiya is a corporate insider, tracked as Chief Financial Officer of NewAmsterdam Pharma Co N.V. (NAMS). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Mayur Ian Somaiya last file a Form 4?
The most recent primary Form 4 on record is dated 22 January 2026, one of 2 filings going back to 2026.
Has Mayur Ian Somaiya been buying or selling stock?
Recorded transactions: 0 open-market purchases and 6 open-market sales ($3.43M) across all tracked filings.
